Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3028 in Advanced Solid Tumors
NCT07589205Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI3028 in solid tumor, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 2 more, sponsored by Innovent Biologics. Primary endpoints: Adverse Events at 3 years, Serious Adverse Events at 3 years and 9 more. Started Mar 2026; status: recruiting.
02
Drugs
IBI3028
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07589205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589205.